Sputnik V Covid-19 vaccine demonstrates 94.3% safety and high efficacy profile in Bahrain

Sputnik V Covid-19 vaccine demonstrates 94.3% safety and high efficacy profile in Bahrain

The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces new data from Bahrain's Ministry of Health, obtained during the Kingdom's national vaccination campaign, confirming the safety and high efficacy of the Russian Sputnik V Covid-19 vaccine. An efficacy study was conducted in Bahrain in accordance with WHO guidelines involving more than 5,000 subjects. Overall efficacy beyond 14 days after administering a second dose was estimated at 94.3%. Analysis is based on data collected between February and early May 2021. The data of the Ministry of Health confirmed that, of those vaccinated with Sputnik V and infected 14 days after their second vaccine dose, 98.6% experienced mild symptoms. Vaccination data indicates high safety of Sputnik V: “¢ No serious adverse events associated with vaccination; “¢ No deaths related to the vaccination; “¢ No cerebral vein thrombosis (CVT) cases after vaccination. Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said: "Sputnik V has demonstrated efficacy of 94.3% and high safety confirming the data collected in a number of other countries where it is used to protect the population against coronavirus. The Russian vaccine is an important part of Bahrain's diversified national portfolio. Use of Sputnik V is making